Update on MRONJ
CE Hours: 1.0
Description: Bone health and maintenance of bone integrity are important concerns during comprehensive cancer care and management of osteoporosis. Bisphosphonates and denosumab are antiresorptive medications widely used for the prevention and treatment of osteoporosis and skeletal complications associated with metastatic cancer and multiple myeloma. Medication-related osteonecrosis of the jaw (MRONJ) related to antiresorptive therapy is a condition that has created numerous dilemmas in patient management and may have a broad health impact. This case-based presentation will review evidence-based data that has led to paradigm shifts for pathogenesis and innovative strategies for risk assessment, prevention and management of MRONJ.
Learning Objectives:
- Describe evidence-based data for risk assessment, diagnosis, and preventive strategies for patients at risk for MRONJ
- Demonstrate endodontic management strategies for patients at risk for MRONJ
- List management options for patients with MRONJ
Key:
Complete
Next
Failed
Available
Locked
Kenneth Fleisher, D.D.S., F.A.C.S.
Dr. Kenneth Fleisher, DDS, FACS is a board certified oral and maxillofacial surgeon, a clinical professor in the department of oral and maxillofacial surgery at the NYU Dentistry, Associate Director of the postgraduate surgery training program and an attending surgeon Bellevue Hospital Center and New York University Langone Medical Center in Plastic Surgery.
Dr. Fleisher is recognized by NYU for his clinical expertise in managing patients undergoing antiresorptive therapy and who have developed medication-related osteonecrosis of the jaw. Dr. Fleisher has published numerous chapters and papers in peer-reviewed journals, lectures nationally and internationally for dental, medical and surgical organizations and he is currently the principal investigator of an interdisciplinary translational research protocol that explores the pathogenesis of osteonecrosis of the jaw.
Speaker Disclosure
I declare that I have no proprietary, financial, or other personal interest of any nature or kind in any product, service, course, and/or company, or in any firm beneficially associated therewith, that will be discussed or considered during the proposed presentation.
